The Lancet November 19, 1994

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Scandinavian Simvastatin Survival Study Group

Bottom Line

The 4S trial demonstrated that lowering cholesterol with the statin simvastatin significantly reduced all-cause and coronary mortality in patients with established coronary heart disease, cementing statins as a cornerstone of secondary prevention.

Key Findings

1. All-cause mortality was significantly reduced in the simvastatin group compared to placebo (8% vs. 12%; Relative Risk [RR] 0.70, 95% CI 0.58-0.85, p=0.0003).

2. Major coronary events occurred in 19% of simvastatin patients versus 28% of placebo patients (RR 0.66, 95% CI 0.59-0.75, p<0.00001).

3. Coronary deaths were markedly lower with simvastatin (111 deaths) compared to placebo (189 deaths), representing a relative risk of 0.58 (95% CI 0.46-0.73).

4. The risk of undergoing myocardial revascularization procedures was reduced by 37% (p<0.00001) in the simvastatin arm.

5. Over the median 5.4-year follow-up, simvastatin produced mean changes in total cholesterol (-25%), LDL cholesterol (-35%), and HDL cholesterol (+8%).

6. The 6-year probabilities of survival were 91.3% in the simvastatin group and 87.6% in the placebo group.

Study Design

Design

RCT

Double-Blind

Sample

4,444

Patients

Duration

5.4 yr

Median

Setting

Multicenter, Scandinavia

Population Men and women aged 35 to 70 years with a history of angina pectoris or acute myocardial infarction, serum total cholesterol between 5.5 and 8.0 mmol/L (213-310 mg/dL), and fasting triglycerides ≤2.5 mmol/L.

Intervention Simvastatin 20 mg once daily, titrated to 40 mg daily if total cholesterol remained >5.2 mmol/L (200 mg/dL).

Comparator Matching placebo once daily.

Outcome All-cause mortality.

Study Limitations

• The cohort consisted exclusively of Scandinavian patients, limiting the immediate generalizability of the findings across diverse racial and ethnic populations.

• The trial excluded patients over the age of 70 at enrollment, leaving unresolved questions at the time regarding statin efficacy and safety in the very elderly.

• The study only enrolled patients with elevated baseline cholesterol (5.5-8.0 mmol/L or ~213-310 mg/dL), which did not definitively establish whether statins benefit secondary prevention patients with "average" or low baseline cholesterol (a question later addressed by the CARE and LIPID trials).

• Patients with significant hypertriglyceridemia (fasting triglycerides >2.5 mmol/L) were excluded.

Clinical Significance

The 4S trial revolutionized cardiovascular medicine by confirming the "lipid hypothesis"—that aggressively lowering LDL cholesterol directly translates to improved survival. The impressive 30% relative risk reduction in all-cause mortality and 34% reduction in major coronary events definitively ended the debate over the utility of lipid-lowering therapy in secondary prevention. It firmly established statins as an essential, life-saving standard of care for patients with atherosclerotic cardiovascular disease, fundamentally shaping all subsequent lipid-management guidelines worldwide.

Historical Context

Prior to the 4S trial, the use of lipid-lowering therapies (such as fibrates, niacin, bile acid sequestrants, or diet) for the secondary prevention of coronary heart disease was highly controversial. Although earlier interventions successfully lowered cholesterol and reduced nonfatal coronary events, they failed to definitively show a reduction in all-cause mortality, and some meta-analyses even suggested a concerning increase in non-cardiovascular deaths (such as accidents or suicides) with cholesterol-lowering. Published in 1994, 4S was the first appropriately powered, randomized, double-blind trial of an HMG-CoA reductase inhibitor (statin) to conclusively prove that pharmacological LDL-lowering substantially reduces both cardiovascular morbidity and total mortality without increasing non-cardiovascular deaths.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does simvastatin exert its lipid-lowering effect at the cellular level, and what compensatory mechanism directly leads to the decreased serum LDL cholesterol observed in the 4S trial?

Key Response

Simvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. This resulting intracellular cholesterol depletion triggers the compensatory upregulation of LDL receptors on the hepatocyte cell surface, which increases the clearance of circulating LDL-C from the blood.

Resident

The 4S trial enrolled patients with established coronary heart disease and elevated baseline cholesterol. Based on this foundational trial and subsequent evidence, how does current management differ for a patient presenting with an acute myocardial infarction who has a 'normal' baseline LDL cholesterol?

Key Response

While 4S targeted patients with hypercholesterolemia, subsequent trials (like the Heart Protection Study) demonstrated cardiovascular benefits regardless of baseline LDL levels. Therefore, current secondary prevention guidelines dictate initiating high-intensity statin therapy for all patients with clinical ASCVD, independent of their baseline LDL-C.

Fellow

The 4S trial demonstrated a remarkable 30% reduction in all-cause mortality, establishing the 'LDL hypothesis'. How much of this early cardiovascular benefit was attributed to absolute LDL reduction versus the pleiotropic effects of statins, and how did later non-statin trials contextualize this?

Key Response

While statins possess pleiotropic effects (plaque stabilization, endothelial function improvement, anti-inflammatory properties), 4S primarily validated the LDL hypothesis. Fellows must recognize that later non-statin lipid-lowering trials (e.g., IMPROVE-IT with ezetimibe, FOURIER with PCSK9 inhibitors) confirmed that absolute cardiovascular risk reduction is predominantly driven by the magnitude of LDL-C lowering, independent of the mechanism, though statin pleiotropy remains relevant in early acute coronary syndrome.

Attending

Prior to 4S, lipid-lowering therapies were viewed with skepticism due to earlier fibrate and diet trials showing increases in non-cardiovascular mortality. How can you use the historical context and outcomes of 4S to address contemporary patient resistance to statin initiation?

Key Response

Before 4S, interventions successfully lowered CHD events but paradoxically increased non-CV deaths (e.g., cancer, suicide), causing massive medical skepticism. 4S was a profound paradigm shift because it proved statins were highly effective for overall survival without increasing non-CV mortality. Attendings can use this history to reassure statin-hesitant patients that statins have decades of rigorous data proving a definitive, life-saving mortality benefit that heavily outweighs the much-publicized mild side effects.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The survival curves in the 4S trial did not begin to diverge until 1-2 years after randomization. How does this latency effect challenge the proportional hazards assumption in survival analysis, and what implications does this have for the statistical design and interim monitoring of future lipid-lowering trials?

Key Response

The delayed separation of Kaplan-Meier curves indicates a violation of the proportional hazards assumption, as the hazard ratio changes over time (initially near 1.0, then decreasing). Researchers must account for this lag time by avoiding premature trial termination for futility and utilizing statistical methods that handle non-proportional hazards or time-varying coefficients to accurately estimate the long-term treatment effect magnitude.

Journal Editor

If reviewing the 4S manuscript today, how would you critically appraise the external validity regarding its demographic inclusion criteria, and what methodological assurances would you demand to ensure the mortality benefit was not confounded by selective loss to follow-up?

Key Response

The 4S cohort was overwhelmingly composed of middle-aged men (only 19% women) and excluded patients older than 70, which significantly limits generalizability to broader ASCVD populations. A critical reviewer would demand strict intention-to-treat (ITT) analyses and a detailed accounting of dropouts (e.g., due to statin intolerance) to verify that the robust mortality benefit was not an artifact of selective attrition of sicker patients from the treatment arm.

Guideline Committee

The 4S trial served as the foundational Level A evidence for lipid lowering in secondary prevention. How have recent ACC/AHA guidelines evolved from the 4S 'target-range' cholesterol approach to the modern framework, and how is the 4S data still reflected in the strength of these recommendations?

Key Response

4S provided the bedrock Class I, Level A evidence that statins reduce mortality in ASCVD. However, whereas 4S aimed for specific cholesterol ranges, the 2013 ACC/AHA guidelines shifted to an 'intensity-based' approach (recommending high-intensity statins for ASCVD). The 2018 ACC/AHA update refined this by maintaining the high-intensity statin foundation established by 4S, but reintroduced an LDL threshold (70 mg/dL) strictly as a trigger to add non-statin adjuncts in very high-risk patients.

Clinical Landscape

Noteworthy Related Trials

1995

West of Scotland Coronary Prevention Study (WOSCOPS)

n = 6,595 · NEJM

Tested

Pravastatin 40 mg daily

Population

Men with hypercholesterolemia and no prior myocardial infarction

Comparator

Placebo

Endpoint

Nonfatal MI or death from coronary heart disease

Key result: Pravastatin significantly reduced the risk of nonfatal myocardial infarction or death from coronary heart disease by 31 percent.

2002

Heart Protection Study (HPS)

n = 20,536 · Lancet

Tested

Simvastatin 40 mg daily

Population

Adults at high risk of coronary heart disease due to prior disease or diabetes

Comparator

Placebo

Endpoint

All-cause mortality and major vascular events

Key result: Simvastatin significantly reduced all-cause mortality and major vascular events, regardless of initial baseline cholesterol levels.

2004

PROVE IT-TIMI 22 Trial

n = 4,162 · NEJM

Tested

Intensive statin therapy (Atorvastatin 80 mg daily)

Population

Patients recently hospitalized for an acute coronary syndrome

Comparator

Moderate statin therapy (Pravastatin 40 mg daily)

Endpoint

Composite of death, MI, unstable angina requiring rehospitalization, revascularization, or stroke

Key result: Intensive lipid-lowering therapy provided greater protection against death or major cardiovascular events than standard moderate lipid-lowering therapy.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis